Hospitals flooded with lucrative requests for health data

As more technology companies are working on healthcare solutions and developing new products, health information and patient data is becoming more valuable––and hospital executives are seeing a flood for requests, according to a report from CNBC.

Selling health information to technology companies is a “lucrative new opportunity” for healthcare executives, CNBC reported, and numerous deals already exist. For example, a deal between Ascension Health, the nation’s largest Catholic health system, and Google allows the tech company to have access to the health information of tens of millions of Ascension patients. That deal has been highly scrutinized in the press and by Congress, but more of these types of projects are likely to forge.

According to one chief information officer of a Texas-based health system, pitches from tech companies come daily. The health data of patients can help software programmers design and train systems to recognize patterns and signs of disease that can lead to better care, but it also could put patient identities and other sensitive information at risk. Hospitals and health systems have scores of patient data and the executives are being “inundated” with requests to strike a deal.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.